New benefits of the second-generation acetylcholinesterase inhibitor rivastigmine ['Exelon'] in the treatment of Alzheimer's disease are now being identified. Studies pointing out these previously unknown benefits were presented at the 52nd Annual Meeting of the American Academy of Neurology [San Diego, US; May 2000].